On the evening of October 30, United Imaging Healthcare (688271. SH) disclosed its third quarter report for 2024. In the first three quarters, the company achieved operating income of 6.954 billion yuan and net profit attributable to the parent company of 671 million yuan. As a leading enterprise of high-end medical equipment in China, United Imaging Healthcare has built the only vertical innovation system covering "complete machine system, core components, and key components" in the industry. At present, the company has basically realized the independent and controllable "whole chain and full product line".

According to the data, in the first three quarters, United Imaging Medical invested a total of 1.635 billion yuan in R&D. As of the end of September this year, the company has launched more than 120 internationally leading products with performance indicators to the market; A total of 8,998 patent applications have been filed, including 7,414 invention patents, accounting for more than 80%.

It is worth noting that since the second half of this year, a number of innovative products of United Imaging Healthcare have been approved for marketing, including the new ultra-large aperture CT system uCT 610 Sim, the new generation of 40-layer intelligent quality control CT system uCT Orion for the private and basic medical markets, and many other innovative products. In particular, at the 2024 Radiotherapy Innovation Conference held in September, the company launched the industry's first integrated CT annular linear accelerator, uLinac HalosTx, ushering in a new era of "precision and efficiency" radiotherapy.

According to reports, the device is based on the integrated CT linear accelerator platform featuring United Imaging, and the machine form is newly designed, and the annular frame and large-aperture CT are innovatively integrated, further highlighting the safety and treatment efficiency of the equipment. In addition, uLinac HalosTx is the industry's first concept of "dual perception of image dose", which can simultaneously observe the patient's "anatomical information" and "dose information" with the blessing of diagnostic-grade CT eagle-eye imaging, ultra-large range of systemic dose monitoring, and intelligent software, achieving a new breakthrough in clinical efficiency and treatment process.